[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sue Brown\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":103},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100631978","insulin-delivery-with-self-adjusting-closed-loop-and-behavioral-glycemic-control-enhanced-by-prediction-100631978",false,"NCT07507708","Insulin Delivery With Self-Adjusting Closed-Loop and Behavioral Glycemic Control Enhanced by Prediction","Insulin Delivery With Self-Adjusting Closed-Loop and Behavioral Glycemic Control Enhanced by Prediction (INSIGHT)","INSIGHT","Participant Inclusion Criteria\n\n1. Age ≥18.0 years old at time of consent\n2. Clinical diagnosis, based on investigator assessment, of T1D for \\> 1 year.\n3. Having used an FDA approved AID system within the last 6 months (can be intermittent use).\n4. Currently using insulin for \\>6 months.\n5. Willingness to switch to use an FDA-approved personal insulin for the study pump (e.g., lispro or aspart, or biosimilar FDA-approved products) as directed by the study team.\n6. Has one or more supportive companions knowledgeable about emergency procedures for severe hypoglycemia and able to contact emergency services and study staff who either lives with participant or located within approximately 30 minutes of participant and able to locate participant in the event of an emergency.\n7. Participant not currently known to be pregnant or breastfeeding.\n8. If participant can become pregnant, they must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative serum or urine pregnancy test will be required for all participants of childbearing potential. Participants who become pregnant will be discontinued from the study. Also, participants who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued.\n9. Willingness to wear a Dexcom CGM during each of the study phases.\n10. Willingness to use the study AIDANET system (CGM, pump, and phone) during the relevant study periods.\n11. Willingness not to start any new non-insulin glucose-lowering agent during the trial.\n12. Willingness to participate in all study procedures including in person training.\n13. Access to internet at home and willingness to upload data during the study as needed.\n14. Investigator has confidence that the participant can successfully operate all study devices and can adhere to the protocol.\n15. Participant is proficient in reading and verbal communication in English.\n\nParticipant Exclusion Criteria The participant must not have any exclusion criteria to be eligible to participate in the study.\n\n1. Plans to start a new non-insulin glucose-lowering agent (e.g., GLP-1 receptor agonists, Symlin, DPP-4 inhibitors,). Participants may be on a stable dose of such an agent for at least the past month.\n2. Current use of sulfonylurea medications.\n3. Uncontrolled microvascular complications such as active proliferative retinopathy not being treated or not responsive to current treatment.\n4. Current use of an SGLT-2 or SGLT-1\u002F2 inhibitor due to risk of euglycemic DKA.\n5. Hemophilia or any other bleeding disorder.\n6. History of severe hypoglycemic events with seizure or loss of consciousness in the last 12 months.\n7. History of DKA event in the last 12 months.\n8. Currently on peritoneal or hemodialysis.\n9. Currently being treated for adrenal insufficiency.\n10. Currently being treated for a seizure disorder.\n11. Hypothyroidism or hyperthyroidism that is not adequately treated.\n12. Use of oral or injectable steroids at the time of enrollment.\n13. Known ongoing adhesive intolerance that is not well managed.\n14. A condition, which in the opinion of the investigator or designee, would put the participant or study at risk.\n15. Participation in another interventional trial at the time of enrollment.\n16. Participant with a direct supervisor at work\u002Fschool who is involved in the conduct of the trial.","ALL","18 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is a randomized cross-over trial comparing AIDANET with Anticipation to AIDANET in FCL without Anticipation. Participants will complete 4 weeks of AID data collection which will be used to establish baseline and initialize the control algorithm. Participants will then be randomized to one of two groups: Group A: AIDANET in FCL with Anticipation (AIDANET+ACL), and Group B: AIDANET in FCL without Anticipation (AIDANET+FCL). The study duration of each group is 4 weeks each. The order of these two phases will be dependent upon randomization.",[27],"Type 1 Diabetes (T1D)",[29,30,31,32,33,34,35],"Automated insulin delivery as Adaptive Network (AIDANET)","Fully automated Closed Loop (FCL)","Hybrid Closed Loop (HCL)","Continuous subcutaneous insulin infusion (CSII)","Insulin Pump","Tandem Mobi system","Anticipatory Closed Loop (ACL)","RECRUITING","2026-06-17",{"date":39,"type":40},"2026-06-22","ACTUAL",{"date":42,"type":40},"2026-05-14",{"date":44,"type":21},"2026-12-31",{"name":46,"class":47},"Sue Brown","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":48},"100632752","effectiveness-of-artificial-intelligence-ai-bolus-priming-added-to-an-existing-fully-automated-control-algorithm-aidanet-100632752","NCT07517770","Effectiveness of Artificial-Intelligence (AI) Bolus Priming Added to an Existing Fully Automated Control Algorithm (AIDANET)","AIDANET AI","Inclusion Criteria:\n\n1. Age ≥18.0 years old at time of consent\n2. Clinical diagnosis, based on investigator assessment, of Type 1 Diabetes (T1D) for at least one year.\n3. Currently using an automated insulin delivery (AID) system.\n4. Willingness to switch to use a commercially approved personal insulin (e.g., lispro or aspart, or biosimilar approved products) within the study pump as directed by the study team.\n5. Has one or more supportive companions knowledgeable about emergency procedures for severe hypoglycemia and able to contact emergency services and study staff that either live with participant or located within approximately 30 minutes of participant and able to locate participant in the event of an emergency.\n6. Participant not currently known to be pregnant or breastfeeding.\n7. If participant can become pregnant, they must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative serum or urine pregnancy test will be required for all females of childbearing potential. Participants who become pregnant will be discontinued from the study. Also, participants who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued.\n8. Willingness to use the study AIDANET system (CGM, insulin pump, and phone) during the study period.\n9. Willingness not to start any new non-insulin glucose-lowering agent during the course of the trial.\n10. Willingness to participate in all study procedures.\n11. Access to internet at home and willingness to upload data during the study as needed.\n12. Investigator has confidence that the participant can successfully operate all study devices and is capable of adhering to the protocol.\n13. Participant is proficient in reading and writing English.\n\nExclusion Criteria:\n\n1. Plans to start a new non-insulin glucose-lowering agent (e.g., Glucagon-like peptide-1 (GLP-1) receptor agonists, Symlin, DPP-4 inhibitors, sulfonylureas). Participants may be on a stable dose of such an agent for at least the past month.\n2. Current use of an sodium-glucose transport protein 2 (SGLT-2) or SGLT-1\u002F2 inhibitor due to risk of euglycemic diabetic ketoacidosis (DKA).\n3. Hemophilia or any other bleeding disorder.\n4. History of severe hypoglycemic events with seizure or loss of consciousness in the last 12 months.\n5. History of DKA event in the last 12 months.\n6. Unstable Stage 4 chronic renal disease or currently on peritoneal or hemodialysis.\n7. Currently being treated for adrenal insufficiency.\n8. Currently being treated for a seizure disorder.\n9. Hypothyroidism or hyperthyroidism that is not adequately treated.\n10. Use of oral or injectable steroids at the time of enrollment or within the last 2 weeks.\n11. Planned surgery during the study period that results in prolonged disconnection from study devices.\n12. Known ongoing adhesive intolerance that is not well managed.\n13. A condition, which in the opinion of the investigator or designee, would put the participant or study at risk.\n14. Participation in another interventional trial at the time of enrollment.\n15. Participant with a direct supervisor involved in the conduct of the trial.",{"count":57,"type":21},50,[24],"Bolus Priming (BP) based on Artificial Intelligence (AI) learning of meal patterns, added to our established Automated insulin delivery as Adaptive Network (AIDANET) algorithm and running on iPhone Diabetes Assistant (iDiAs) phone wirelessly connected to Tandem Mobi insulin pump and Dexcom Continuous Glucose Monitor (CGM).",[61],"Type 1 Diabetes Mellitis",[27,63,31,64,65,66,67,68,69],"Artificial-Intelligence (AI)","Fully Closed Loop (FCL)","Mobi insulin pump","iPhone Diabetes Assistant (iDiAs)","Automated insulin delivery as Adaptive Network (AIDANET) algorithm","Bolus Priming System (BPS)","Mobi Research App (MRA)","NOT_YET_RECRUITING","2026-04-03",{"date":73,"type":40},"2026-04-08",{"date":75,"type":21},"2026-05-01",{"date":77,"type":21},"2027-04-30",{"name":46,"class":47},{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":48},"100595989","a-randomized-parallel-clinical-trial-of-aidanet-an-automated-insulin-delivery-algorithm-in-fully-closed-loop-vs-hybrid-closed-loop-mode-in-adults-with-type-1-diabetes-aidanet-at-home-100595989","NCT07039617","A Randomized Parallel Clinical Trial of AIDANET, an Automated Insulin Delivery Algorithm, in Fully Closed-Loop Vs Hybrid Closed-Loop Mode In Adults With Type 1 Diabetes (AIDANET At Home)","Inclusion Criteria:\n\n1. Age ≥18.0 years old at time of consent\n2. Clinical diagnosis, based on investigator assessment, of Type 1 Diabetes for at least one year.\n3. Having used an Food and Drug Administration (FDA) approved AID system within the last six months (can be intermittent use).\n4. Currently using insulin for at least six months.\n5. Willingness to switch to use an FDA-approved personal insulin for the study pump (e.g., lispro or aspart, or biosimilar FDA-approved products) as directed by the study team.\n6. Has one or more supportive companions knowledgeable about emergency procedures for severe hypoglycemia and able to contact emergency services and study staff who either lives with participant or located within approximately 30 minutes of participant and able to locate participant in the event of an emergency.\n7. Participant not currently known to be pregnant or breastfeeding.\n8. If participant capable of becoming pregnant, must agree to use a form of contraception to prevent pregnancy while a participant in the study (e.g. hormonal contraception, abstinence from heterosexual intercourse). A negative serum or urine pregnancy test will be required for all participants of childbearing potential. Participants who become pregnant will be discontinued from the study. Also, participants who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued.\n9. Willingness to wear a Dexcom CGM during each of the four study phases.\n10. Willingness to use the study AIDANET system (CGM, pump, and phone) during the relevant study periods.\n11. Willingness not to start any new non-insulin glucose-lowering agent during the course of the trial.\n12. Willingness to participate in all study procedures including in person training.\n13. Access to internet at home and willingness to upload data during the study as needed.\n14. Investigator has confidence that the participant can successfully operate all study devices and is capable of adhering to the protocol.\n15. Participant is proficient in reading and verbal communication in English.\n\nExclusion Criteria:\n\n1. Plans to start a new non-insulin glucose-lowering agent (e.g. glucagon-like peptide-1 (GLP-1) receptor agonists, Symlin, (DPP-4 inhibitors, also known as dipeptidyl peptidase 4). Participants may be on a stable dose of such an agent for at least the past month.\n2. Current use of sulfonylurea medications.\n3. Current use of an Sodium-Glucose Cotransporter 2 (also known as a SGLT-2 or SGLT-1\u002F2 inhibitor) due to risk of euglycemic diabetic ketoacidosis (DKA).\n4. Hemophilia or any other bleeding disorder.\n5. History of severe hypoglycemic events with seizure or loss of consciousness in the last 12 months.\n6. History of DKA event in the last 12 months.\n7. Currently on peritoneal or hemodialysis.\n8. Currently being treated for adrenal insufficiency.\n9. Currently being treated for a seizure disorder.\n10. Hypothyroidism or hyperthyroidism is not adequately treated.\n11. Use of oral or injectable steroids at the time of enrollment.\n12. Known ongoing adhesive intolerance that is not well managed.\n13. A condition, which in the opinion of the investigator or designee, would put the participant or study at risk.\n14. Participation in another interventional trial at the time of enrollment.\n15. Participant with a direct supervisor at work\u002Fschool who is involved in the conduct of the trial.",{"count":86,"type":21},40,[24],"A randomized cross-over trial assessing glycemic control on Automated insulin delivery as Adaptive Network (AIDANET) algorithm when used in three modes: AIDANET-Fully Closed Loop (FCL), AIDANET-Hybrid Closed Loop (HCL) and AIDANET allowing a mix between FCL and HCL. There will be an Automated Insulin Delivery (AID) phase with participants using their home devices and\u002For study continuous glucose monitor (CGM) and study-provided commercial Mobi system without AIDANET.",[90],"Type 1 Diabetes",[92,64,31,93,94],"Automated Insulin Delivery (AID)","Specifically modified Mobi System","Automated Insulin Delivery as Adaptive NETwork (AIDANET)","2026-03-27",{"date":97,"type":40},"2026-04-02",{"date":99,"type":40},"2025-09-02",{"date":101,"type":21},"2026-07-31",{"name":46,"class":47},""]